1384477-13-7

Upstream product

• 288-32-4 1H-imidazole 
• 23138-53-6 methyl 4-isocyanatobenzoate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 619-45-4 4-methoxycarbonyl aniline 

Downstream Products

• 288-32-4 1H-imidazole 
• 23138-53-6 methyl 4-isocyanatobenzoate 
• 53865-58-0 methyl 4-[(phenylcarbamoyl)amino]benzoate 
• 53405-05-3 N-formyl p-aminobenzoic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: Kinetics and application

N-Carbamoylimidazoles dissociate in solution to yield imidazole and an isocyanate that may be reacted with another aryl amine to form an unsymmetrical biaryl urea. This paper investigates the reaction kinetics and the influence of electron withdrawing/donating substituents on the reaction of N-carbamoylimidazoles with aniline. The overall reaction mechanism involves two zwitterionic intermediates, formed during dissociation and upon reaction of the liberated isocyanate with aniline. The rate limiting step for the reaction is a base catalysed proton transfer from the second zwitterionic intermediate. Although electron withdrawing substituents on the aryl group hinder dissociation, they significantly increase reaction rates compared to compounds bearing electron donating substituents. The imidazole liberated upon dissociation catalyses the rate determining step so that reactions of dissociated N-carbamoylimidazoles proceed more rapidly than those involving only isocyanates. In addition, the imidazole eliminates the need for anhydrous reaction conditions. The N-carbamoylimidazole methodology was demonstrated by preparing sorafenib, a biaryl urea kinase inhibitor, in good yield and excellent purity.

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

FXR receptor modulator, and preparation method and application thereof

The invention discloses a FXR receptor modulator, and a preparation method and application thereof, belonging to the field of pharmaceutical chemistry. The FXR receptor modulator with structural characteristics as shown in a formula I which is described i